The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing &#x03B1; &#x03BD; &#x03B2; 3  integrin in chick embryo and nude mouse models

Yasunori Tome; Hiroaki Kimura; Naotoshi Sugimoto; Hiroyuki Tsuchiya; Fuminori Kanaya; Michael Bouvet; Robert M. Hoffman

doi:10.18632/oncotarget.13497

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing α_νβ₃ integrin in chick embryo and nude mouse models

Yasunori Tome, Hiroaki Kimura, Naotoshi Sugimoto, Hiroyuki Tsuchiya, Fuminori Kanaya, Michael Bouvet and Robert M. Hoffman _

PDF | HTML | How to cite

Oncotarget. 2016; 7:87031-87036. https://doi.org/10.18632/oncotarget.13497

Metrics: PDF 1436 views | HTML 2147 views | ?

Abstract

Yasunori Tome1,2,3, Hiroaki Kimura1,4, Naotoshi Sugimoto5, Hiroyuki Tsuchiya4, Fuminori Kanaya3, Michael Bouvet2, Robert M. Hoffman1,2

1AntiCancer, Inc., San Diego, CA 92111, USA

2Department of Surgery, University of California, San Diego, CA 92103, USA

3Department of Orthopedic Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, 903-0125 Japan

4Department of Orthopaedic Surgery, Graduate School of Medical Science, Kanazawa University, Kanazawa, 920-8641 Japan

5Department of Physiology, Graduate School of Medical Science, Kanazawa University, Kanazawa, 920-8641 Japan

Correspondence to:

Robert M. Hoffman, email: [email protected]

Keywords: α_vβ₃ integrin, echistatin, green fluorescent protein, red fluorescent protein, osteosarcoma, nude mice, orthotopic

Received: September 20, 2016 Accepted: October 27, 2016 Published: November 22, 2016

ABSTRACT

Echistatin, a cyclic RGD peptide, which is an antagonist of α_vβ₃ integrin (disintegrin), inhibited human osteosarcoma in the chick chorioallontoic membrane (CAM) model and tumor growth and pulmonary metastases in a nude mouse orthotopic model. A high-metastatic variant of human osteosarcoma, 143B-LM4, overexpressing α_vβ₃ integrin was used. Tumor angiogenesis by high-metastatic variant 143B-LM4 cells in the CAM was significantly inhibited by echistatin (P<0.05) as was overall growth. A doxorubicin (DOX)-echistatin combination inhibited orthotopic tumor growth compared to untreated control (P<0.01) or DOX alone (P<0.05) in nude mice. Tumor-bearing mice treated with the DOX-echistatin combination survived longer than those treated with DOX alone or control PBS (P<0.01 and P<0.01, respectively). Echistatin also inhibited experimental lung metastasis of 143B-LM4 cells in nude mice. These results suggest that DOX in combination with a disintegrin has potential to treat osteosarcoma and that α_vβ₃ integrin may be a target for osteosarcoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13497

Publication Alerts

Research Papers:

The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing ανβ3 integrin in chick embryo and nude mouse models

Abstract

The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing α_νβ₃ integrin in chick embryo and nude mouse models